Trials / Completed
CompletedNCT00189280
Aldara for the Treatment of Large and/or Multiple sBCC
Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- MEDA Pharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
BCC is the most common form of skin cancer. Current treatment is often surgery but this can be limited by the number of lesions, their location the age of the patient or the potential cosmetic outcome. The purpose of this study is to evaluate the effectiveness of imiquimod, on a non surgical treatment, in subjects with multiple of large sBCCs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod | cream 5%, 5 days out of seven, for 6 weeks |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2005-09-19
- Last updated
- 2022-02-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00189280. Inclusion in this directory is not an endorsement.